| Item Type | Name |
|
Concept
|
Leukemia, B-Cell
|
|
Concept
|
Leukemia, Hairy Cell
|
|
Concept
|
Leukemia, T-Cell
|
|
Academic Article
|
Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine.
|
|
Academic Article
|
Acute myeloid leukaemia following interferon-alfa treatment of hairy cell leukaemia.
|
|
Academic Article
|
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
|
|
Academic Article
|
Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method.
|
|
Academic Article
|
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
|
|
Academic Article
|
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
|
|
Academic Article
|
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
|
|
Academic Article
|
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
|
|
Academic Article
|
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
|
|
Academic Article
|
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
|
|
Academic Article
|
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
|
|
Academic Article
|
Chronic lymphocytic leukemia masquerading as uveitis.
|
|
Academic Article
|
Nelarabine in the treatment of refractory T-cell malignant diseases.
|
|
Academic Article
|
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
|
|
Academic Article
|
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
|
|
Academic Article
|
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
|
|
Academic Article
|
Cardiac tamponade in a patient with chronic lymphocytic leukemia.
|
|
Academic Article
|
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
|
|
Academic Article
|
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
|
|
Academic Article
|
Cytochalasin B is a potent mitogen for chronic lymphocytic leukemia cells in vitro.
|
|
Academic Article
|
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Mevalonic acid induces DNA synthesis in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
|
|
Academic Article
|
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
|
|
Academic Article
|
Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia.
|
|
Academic Article
|
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
|
|
Academic Article
|
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
|
|
Academic Article
|
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.
|
|
Academic Article
|
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
|
|
Academic Article
|
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).
|
|
Academic Article
|
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
|
|
Academic Article
|
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.
|
|
Academic Article
|
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
|